BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
The approval was supported by the TRIDENT-1 trial studying Augtyro in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC.
The approval was supported by the TRIDENT-1 trial studying Augtyro in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC.
What's Your Reaction?
